Clinical Trial

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.
Protocol Amendment History 1 change
notable Trial sites expanded: 6 -> 14 locations 2026-04-09
Trial Details
NCT Number NCT07502508
Lead Sponsor Biomea Fusion Inc.
Conditions Type 2 Diabetes
Enrollment 60 participants
Start Date 2026-04-30
Primary Completion 2027-06 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-15